How long does it take for ivonib to be effective? How to adjust the treatment plan after drug resistance?

Ivosidenib is a targeted drug mainly used to treat IDH1 mutation-positive acute myeloid leukemia (AML) and other related malignant tumors. For most patients, the effects of ivosidenib usually take weeks to months to develop. Generally speaking, after patients use ivonib, doctors will regularly monitor hematological response and tumor marker levels to evaluate whether the drug is effective. The manifestation of efficacy is related to the severity of the patient's disease, the type of mutation and the individual response to treatment.

In the early stages of treatment, some patients may experience relief of symptoms, gradual improvement in blood routine indicators, and even complete clinical remission. For other patients, it may take longer to see the therapeutic effects of the medication. The persistence and efficacy of treatment are usually noticeable within 3 to 6 months. The doctor will adjust the treatment plan according to the patient's specific condition to ensure that the drug has the best effect.

However, as treatment progresses, some patients may develop drug resistance. Resistance to ivonib is usually associated with mutations in the IDH1 gene locus in tumor cells, resulting in ineffective drug action. Symptoms of drug resistance include disease recurrence and hematological indicators failing to improve or continuing to worsen. In this case, the patient's treatment plan needs to be adjusted, which may include switching to other targeted drugs, combination chemotherapy, or immunotherapy.

For adjustments to treatment after drug resistance, doctors usually make personalized adjustments based on the patient's specific condition, drug resistance mechanism and existing treatment options. Consider increasing the drug dose, switching to other drugs, or combining other treatments to overcome resistance. Additionally, new treatments in clinical trials may become viable options, providing patients with more treatment opportunities. In short, during the treatment with ivonib, patients should be followed up regularly, work closely with their doctors, and adjust the treatment plan according to the treatment response.

Reference link:https://www.tibsovo.com/